Immunotherapy for Prostate Cancer: Where We Are Headed

Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has bec...

Descripción completa

Detalles Bibliográficos
Autores principales: Schepisi, Giuseppe, Farolfi, Alberto, Conteduca, Vincenza, Martignano, Filippo, De Lisi, Delia, Ravaglia, Giorgia, Rossi, Lorena, Menna, Cecilia, Bellia, Salvatore Roberto, Barone, Domenico, Gunelli, Roberta, De Giorgi, Ugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751230/
https://www.ncbi.nlm.nih.gov/pubmed/29206214
http://dx.doi.org/10.3390/ijms18122627
_version_ 1783289903176482816
author Schepisi, Giuseppe
Farolfi, Alberto
Conteduca, Vincenza
Martignano, Filippo
De Lisi, Delia
Ravaglia, Giorgia
Rossi, Lorena
Menna, Cecilia
Bellia, Salvatore Roberto
Barone, Domenico
Gunelli, Roberta
De Giorgi, Ugo
author_facet Schepisi, Giuseppe
Farolfi, Alberto
Conteduca, Vincenza
Martignano, Filippo
De Lisi, Delia
Ravaglia, Giorgia
Rossi, Lorena
Menna, Cecilia
Bellia, Salvatore Roberto
Barone, Domenico
Gunelli, Roberta
De Giorgi, Ugo
author_sort Schepisi, Giuseppe
collection PubMed
description Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients.
format Online
Article
Text
id pubmed-5751230
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-57512302018-01-08 Immunotherapy for Prostate Cancer: Where We Are Headed Schepisi, Giuseppe Farolfi, Alberto Conteduca, Vincenza Martignano, Filippo De Lisi, Delia Ravaglia, Giorgia Rossi, Lorena Menna, Cecilia Bellia, Salvatore Roberto Barone, Domenico Gunelli, Roberta De Giorgi, Ugo Int J Mol Sci Review Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients. MDPI 2017-12-05 /pmc/articles/PMC5751230/ /pubmed/29206214 http://dx.doi.org/10.3390/ijms18122627 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Schepisi, Giuseppe
Farolfi, Alberto
Conteduca, Vincenza
Martignano, Filippo
De Lisi, Delia
Ravaglia, Giorgia
Rossi, Lorena
Menna, Cecilia
Bellia, Salvatore Roberto
Barone, Domenico
Gunelli, Roberta
De Giorgi, Ugo
Immunotherapy for Prostate Cancer: Where We Are Headed
title Immunotherapy for Prostate Cancer: Where We Are Headed
title_full Immunotherapy for Prostate Cancer: Where We Are Headed
title_fullStr Immunotherapy for Prostate Cancer: Where We Are Headed
title_full_unstemmed Immunotherapy for Prostate Cancer: Where We Are Headed
title_short Immunotherapy for Prostate Cancer: Where We Are Headed
title_sort immunotherapy for prostate cancer: where we are headed
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751230/
https://www.ncbi.nlm.nih.gov/pubmed/29206214
http://dx.doi.org/10.3390/ijms18122627
work_keys_str_mv AT schepisigiuseppe immunotherapyforprostatecancerwhereweareheaded
AT farolfialberto immunotherapyforprostatecancerwhereweareheaded
AT conteducavincenza immunotherapyforprostatecancerwhereweareheaded
AT martignanofilippo immunotherapyforprostatecancerwhereweareheaded
AT delisidelia immunotherapyforprostatecancerwhereweareheaded
AT ravagliagiorgia immunotherapyforprostatecancerwhereweareheaded
AT rossilorena immunotherapyforprostatecancerwhereweareheaded
AT mennacecilia immunotherapyforprostatecancerwhereweareheaded
AT belliasalvatoreroberto immunotherapyforprostatecancerwhereweareheaded
AT baronedomenico immunotherapyforprostatecancerwhereweareheaded
AT gunelliroberta immunotherapyforprostatecancerwhereweareheaded
AT degiorgiugo immunotherapyforprostatecancerwhereweareheaded

Ejemplares similares